![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-desktop-headergif-72716.gif)
![EuroAPI Header](https://www.pharmacompass.com/image/flap/euroapi-w34-mob-headergif-95876.gif)
Upload your Marketing & Sales content on your company Virtual Booth, click HERE.
https://www.indianpharmapost.com/news/glenmark-therapeutics-launches-olopatadine-hydrochloride-ophthalmic-solution-usp-16050
https://www.indianpharmapost.com/news/glenmark-pharma-reports-q1-fy25-consolidated-pat-at-rs-3402-cr-16034
https://www.pharmacompass.com/pdf/news/enforcement-report-for-week-of-august-7-2024-64880.pdf
https://www.pharmacompass.com/pdf/news/enforcement-report-week-of-july-24-2024-12306.pdf
https://www.moneycontrol.com/news/business/glenmark-pharma-gets-usfda-nod-for-seizure-treatment-drug-2-12770924.html
https://www.fiercepharma.com/pharma/glenmark-recalls-114-batches-low-potassium-drug-us-over-potentially-deadly-hyperkalemia-risk
https://www.fda.gov/safety/recalls-market-withdrawals-safety-alerts/glenmark-pharmaceuticals-inc-usa-issues-voluntary-nationwide-recall-potassium-chloride-extended#:~:text=The%20product%20is%20being%20recalled,can%20lead%20to%20cardiac%20arrest.
https://economictimes.indiatimes.com/industry/healthcare/biotech/pharmaceuticals/glenmark-gets-usfda-nod-to-market-generic-drug/articleshow/110929992.cms
https://www.accessdata.fda.gov/scripts/cder/daf/index.cfm?event=overview.process&ApplNo=218092